| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
10.91(B) |
| Last
Volume: |
1,933,966 |
Avg
Vol: |
1,913,064 |
| 52
Week Range: |
$56.27 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
103,519 |
108,398 |
180,881 |
290,334 |
| Total Sell Value |
$6,219,303 |
$6,570,910 |
$12,429,896 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
49 |
52 |
65 |
100 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Herriott James |
General Counsel |
• – – |
2023-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
883 |
9,495 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-13 |
4 |
AS |
$64.55 |
$74,749 |
D/D |
(1,158) |
20,549 |
|
42% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-13 |
4 |
AS |
$64.55 |
$292,218 |
D/D |
(4,527) |
1,173,105 |
|
42% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,579 |
21,707 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,705 |
1,177,632 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-02-01 |
4 |
AS |
$67.93 |
$67,930 |
D/D |
(1,000) |
84,090 |
|
34% |
|
| Doyle James Edward |
Director |
– • – |
2023-01-13 |
4 |
OE |
$16.52 |
$90,480 |
D/D |
5,477 |
53,913 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-01-09 |
4 |
AS |
$60.00 |
$60,000 |
D/D |
(1,000) |
85,090 |
|
38% |
|
| Coward D Scott |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,780 |
24,342 |
|
- |
|
| Herriott James |
General CounselOfficer |
• – – |
2022-12-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
613 |
|
58% |
|
| Herriott James |
General CounselOfficer |
• – – |
2022-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,612 |
|
58% |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2022-10-12 |
4 |
AS |
$31.37 |
$529,275 |
D/D |
(16,872) |
18,654 |
|
90% |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2022-10-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,006 |
35,526 |
|
- |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2022-08-05 |
4 |
AS |
$47.12 |
$46,366 |
D/D |
(984) |
4,596 |
|
10% |
|
| Baranick Brian |
Gen. Mgr., Precision OncologyO |
• – – |
2022-08-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
159 |
|
-10% |
|
| Baranick Brian |
Gen. Mgr., Precision OncologyO |
• – – |
2022-08-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,868 |
|
-10% |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2022-08-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,712 |
5,580 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2022-07-26 |
4 |
AS |
$45.14 |
$208,005 |
D/D |
(4,608) |
60,318 |
|
2% |
|
| Napier Katherine S |
Director |
– • – |
2022-07-26 |
4 |
OE |
$10.18 |
$46,909 |
D/D |
4,608 |
64,926 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2022-07-01 |
4 |
AS |
$40.75 |
$285 |
D/D |
(7) |
1,167,927 |
|
7% |
|
| Napier Katherine S |
Director |
– • – |
2022-06-30 |
4 |
AS |
$40.13 |
$43,581 |
D/D |
(1,086) |
60,318 |
|
2% |
|
| Clancy Paul J |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
5,606 |
11,102 |
|
- |
|
| Sebelius Kathleen |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,523 |
21,400 |
|
- |
|
| Lewis-Hall Freda C |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
5,606 |
16,089 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
5,606 |
48,436 |
|
- |
|
957 Records found
|
|
Page 8 of 39 |
|
|
1.94 (3.06%) 
